Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7
|
作者：
Kollmannsberger, Christian [1 ]
Mitchell, Teresa [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
来源：
SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期
关键词：
RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;
D O I：
10.1053/j.seminoncol.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：499 / 510
页数：12
相关论文
共 50 条
  • [11] Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma
    Anh Pham
    Ye, Da-Wei
    Pal, Sumanta
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (12) : 517 - 527
  • [12] Healing and targeted therapies: Management in perioperative period?
    Pignot, G.
    Lebret, T.
    Chekulaev, D.
    Peyromaure, M.
    Saighi, D.
    Flam, T.
    Amsellem-Ouazana, D.
    Debre, B.
    Zerbib, M.
    PROGRES EN UROLOGIE, 2011, 21 (03): : 166 - 172
  • [13] Surgical management of metastatic renal cell carcinoma in the era of targeted therapies
    Krabbe, Laura-Maria
    Haddad, Ahmed Q.
    Westerman, Mary E.
    Margulis, Vitaly
    WORLD JOURNAL OF UROLOGY, 2014, 32 (03) : 615 - 622
  • [14] Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
    Gore, M. E.
    Larkin, J. M. G.
    BRITISH JOURNAL OF CANCER, 2011, 104 (03) : 399 - 406
  • [15] Biological therapies in breast cancer: Common toxicities and management strategies
    Barroso-Sousa, Romualdo
    Santana, Iuri A.
    Testa, Laura
    Gagliato, Debora de Melo
    Mano, Max S.
    BREAST, 2013, 22 (06) : 1009 - 1018
  • [16] Targeted therapies for renal cell carcinoma: more gains from using them again
    Gan, H. K.
    Seruga, B.
    Knox, J. J.
    CURRENT ONCOLOGY, 2009, 16 : S47 - S53
  • [17] Management of side effects of targeted therapies in renal cancer: nephrological side effects
    Izzedine, Hassan
    Negrier, Sylvie
    Neuzillet, Yann
    Zini, Laurent
    BULLETIN DU CANCER, 2011, 98 : S7 - S18
  • [18] Digestive neuroendocrine tumors (DNET): The era of targeted therapies
    Boussaha, Tarek
    Rougier, Philippe
    Taieb, Julien
    Lepere, Celine
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (02) : 134 - 141
  • [19] Sunitinib and other targeted therapies for renal cell carcinoma
    Powles, T.
    Chowdhury, S.
    Jones, R.
    Mantle, M.
    Nathan, P.
    Bex, A.
    Lim, L.
    Hutson, T.
    BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 741 - 745
  • [20] Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma: Practical Management Strategies in the Second-Line Setting
    Creel, Patricia A.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2014, 18 (06) : 694 - 700
12345